Outcomes for each prioritized question
| . | Critical outcomes for decision-making . | |
|---|---|---|
| Q1. | • Time to transfusion (delay to treatment) | |
| • Time to antibody identification | ||
| • Alloimmunization | ||
| • HTR | ||
| • Mortality | ||
| • Morbidity | ||
| Q2. | • HTR | |
| • Alloimmunization rate | ||
| • Alloimmunization prevalence | ||
| • Morbidity | ||
| • Mortality | ||
| Q3. | • Alloimmunization | |
| • HTR | ||
| • ICU admission | ||
| • Mortality | ||
| • Infection | ||
| • Pain | ||
| • Adverse effects (aseptic meningitis, avascular necrosis [AVN]) | ||
| Q4. | • Length of stay | |
| • Morbidity (stroke, renal function) | ||
| • Mortality | ||
| • Infection (meningococcemia, hepatitis B reactivation) | ||
| • Pain | ||
| • Adverse effects (aseptic meningitis, AVN) | ||
| Q5. | • Alloimmunization | |
| • RBC unit use | ||
| • Frequency of visits | ||
| • Iron overload | ||
| • HbS suppression | ||
| • Recurrence or progression of primary indication for chronic transfusion (stroke, acute chest syndrome, pain) | ||
| • Adverse reactions (fever, allergic, procedural such as nausea, citrate toxicity, hypotension, presyncope) | ||
| • Line-related complications | ||
| • Duration of procedure | ||
| Q6. | • Length of hospital stay | |
| • Length of ICU stay | ||
| • Ventilator support (days) | ||
| • Morbidity (during hospital stay) | ||
| • Mortality | ||
| • HbS level | ||
| • Alloimmunization | ||
| • Adverse reactions (fever, allergic, fluid overload, procedural such as nausea, citrate toxicity, thrombocytopenia) | ||
| • Line-related complication | ||
| Q7. | • RBC unit use | |
| • Frequency of procedures | ||
| • Iron overload | ||
| • HbS suppression | ||
| • Recurrence or progression of primary indication for chronic transfusion (stroke, acute chest syndrome, pain) | ||
| • Alloimmunization | ||
| • Adverse reactions | ||
| • Duration of procedure | ||
| Q8. | • Alloimmunization | |
| • Maternal mortality | ||
| • Vaso-occlusive pain episodes | ||
| • Pulmonary complications | ||
| • Pulmonary embolism | ||
| • Pyelonephritis | ||
| • Perinatal mortality | ||
| • Small size for gestational age/low birth weight | ||
| • Neonatal death | ||
| • Preterm birth | ||
| Q9. | • Postoperative acute chest syndrome | |
| • Postoperative pain crisis | ||
| • All other postoperative complications (infection, thrombosis) | ||
| • Mortality | ||
| • Alloimmunization | ||
| • Adverse reactions (allergic, fever) | ||
| • Length of stay | ||
| Q10. | • Iron-induced liver disease/failure | |
| • Iron-induced cardiac disease | ||
| • Iron-induced endocrinopathies (growth failure, delayed puberty, hypothyroidism, diabetes) | ||
| • Mortality | ||
| . | Critical outcomes for decision-making . | |
|---|---|---|
| Q1. | • Time to transfusion (delay to treatment) | |
| • Time to antibody identification | ||
| • Alloimmunization | ||
| • HTR | ||
| • Mortality | ||
| • Morbidity | ||
| Q2. | • HTR | |
| • Alloimmunization rate | ||
| • Alloimmunization prevalence | ||
| • Morbidity | ||
| • Mortality | ||
| Q3. | • Alloimmunization | |
| • HTR | ||
| • ICU admission | ||
| • Mortality | ||
| • Infection | ||
| • Pain | ||
| • Adverse effects (aseptic meningitis, avascular necrosis [AVN]) | ||
| Q4. | • Length of stay | |
| • Morbidity (stroke, renal function) | ||
| • Mortality | ||
| • Infection (meningococcemia, hepatitis B reactivation) | ||
| • Pain | ||
| • Adverse effects (aseptic meningitis, AVN) | ||
| Q5. | • Alloimmunization | |
| • RBC unit use | ||
| • Frequency of visits | ||
| • Iron overload | ||
| • HbS suppression | ||
| • Recurrence or progression of primary indication for chronic transfusion (stroke, acute chest syndrome, pain) | ||
| • Adverse reactions (fever, allergic, procedural such as nausea, citrate toxicity, hypotension, presyncope) | ||
| • Line-related complications | ||
| • Duration of procedure | ||
| Q6. | • Length of hospital stay | |
| • Length of ICU stay | ||
| • Ventilator support (days) | ||
| • Morbidity (during hospital stay) | ||
| • Mortality | ||
| • HbS level | ||
| • Alloimmunization | ||
| • Adverse reactions (fever, allergic, fluid overload, procedural such as nausea, citrate toxicity, thrombocytopenia) | ||
| • Line-related complication | ||
| Q7. | • RBC unit use | |
| • Frequency of procedures | ||
| • Iron overload | ||
| • HbS suppression | ||
| • Recurrence or progression of primary indication for chronic transfusion (stroke, acute chest syndrome, pain) | ||
| • Alloimmunization | ||
| • Adverse reactions | ||
| • Duration of procedure | ||
| Q8. | • Alloimmunization | |
| • Maternal mortality | ||
| • Vaso-occlusive pain episodes | ||
| • Pulmonary complications | ||
| • Pulmonary embolism | ||
| • Pyelonephritis | ||
| • Perinatal mortality | ||
| • Small size for gestational age/low birth weight | ||
| • Neonatal death | ||
| • Preterm birth | ||
| Q9. | • Postoperative acute chest syndrome | |
| • Postoperative pain crisis | ||
| • All other postoperative complications (infection, thrombosis) | ||
| • Mortality | ||
| • Alloimmunization | ||
| • Adverse reactions (allergic, fever) | ||
| • Length of stay | ||
| Q10. | • Iron-induced liver disease/failure | |
| • Iron-induced cardiac disease | ||
| • Iron-induced endocrinopathies (growth failure, delayed puberty, hypothyroidism, diabetes) | ||
| • Mortality | ||